Compare · BIO vs OLK
BIO vs OLK
Side-by-side comparison of Bio-Rad Laboratories Inc. (BIO) and Olink Holding AB (OLK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIO and OLK operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO carries a market cap of $8.16B.
- BIO has hit the wire 1 time in the past 4 weeks while OLK has been quiet.
- BIO has more recent analyst coverage (12 ratings vs 3 for OLK).
- Company
- Bio-Rad Laboratories Inc.
- Olink Holding AB
- Price
- $304.75-0.42%
- $26.01+0.04%
- Market cap
- $8.16B
- -
- 1M return
- +18.20%
- -
- 1Y return
- +37.16%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1980
- 2021
- News (4w)
- 1
- 0
- Recent ratings
- 12
- 3
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Olink Holding AB
Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. The company's products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, it provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of NPX data. Olink Holding AB (publ) sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden. Olink Holding AB (publ) is a subsidiary of Summa Equity Holding AB.
Latest BIO
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
- Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
- Bio-Rad Reports Third-Quarter 2025 Financial Results
- Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
Latest OLK
- SEC Form 15F-12B filed by Olink Holding AB
- SEC Form 6-K filed by Olink Holding AB
- Amendment: SEC Form SC 14D9/A filed by Olink Holding AB
- Amendment: SEC Form SC TO-T/A filed by Olink Holding AB
- SEC Form 6-K filed by Olink Holding AB
- Notice to attend the Extra General Meeting of Olink Holding AB (publ)
- SEC Form 6-K filed by Olink Holding AB
- SEC Form S-8 POS filed by Olink Holding AB
- SEC Form S-8 POS filed by Olink Holding AB
- SEC Form S-8 POS filed by Olink Holding AB